GlassScriptPhysician profile
Hassan Ismail
NPI 1881687861
$6,171.38
in general payments reported to CMS, 2019-2025
33 companies · $686 in 2025
The $686 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $243 · 2021: $623 · 2022: $1,476 · 2023: $1,586 · 2024: $1,089 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,248.58 | 2019-2025 | |
| Abiomed | $919.84 | 2021-2025 | Impella |
| Inari Medical, INC. | $576.39 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $529.72 | 2021-2025 | Corevalve Evolut R |
| Amgen INC. | $400.41 | 2019-2024 | Repatha |
| Merck Sharp & Dohme LLC | $293.77 | 2021-2024 | Verquvo |
| Abbott Laboratories | $276.24 | 2021-2025 | Aveir, Diamondback Peripheral, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $179.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $174.37 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $149.00 | 2023-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.17 | 2021-2024 | Jardiance |
| Shockwave Medical, INC | $130.95 | 2022 | |
| Penumbra, INC. | $116.30 | 2022 | |
| Scpharmaceuticals INC. | $113.56 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $110.92 | 2022-2023 | Assure Wcd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.00 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $102.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $101.36 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $74.14 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $73.30 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $53.11 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $48.39 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $41.93 | 2021-2025 | Onpattro |
| Terumo Medical Corporation | $33.63 | 2020 | |
| Vital Connect, INC | $28.02 | 2024 | Vitalpatch Rtm |
| Bardy Diagnostics, INC. | $23.88 | 2021 | |
| Lundbeck LLC | $23.30 | 2019 | |
| Daiichi Sankyo INC. | $21.04 | 2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $20.25 | 2021 | |
| Cordis US Corp. | $19.71 | 2024 | Mynx Control |
| Regeneron Healthcare Solutions, INC. | $16.22 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.57 | 2020 | |
| Ekos Corporation | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.